JP2013525420A - 抗ｃｄ３免疫分子療法により肝炎を治療する方法および組成物 - Google Patents

抗ｃｄ３免疫分子療法により肝炎を治療する方法および組成物 Download PDF

Info

Publication number
JP2013525420A
JP2013525420A JP2013506803A JP2013506803A JP2013525420A JP 2013525420 A JP2013525420 A JP 2013525420A JP 2013506803 A JP2013506803 A JP 2013506803A JP 2013506803 A JP2013506803 A JP 2013506803A JP 2013525420 A JP2013525420 A JP 2013525420A
Authority
JP
Japan
Prior art keywords
hepatitis
antibody
oral
administration
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013506803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525420A5 (https=
Inventor
イラン，ヤロン
エリス，ロナルド
Original Assignee
ナスバックス リミテッド
ハダシット メディカル リサーチ サービス アンド ディベロップメント カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナスバックス リミテッド, ハダシット メディカル リサーチ サービス アンド ディベロップメント カンパニー リミテッド filed Critical ナスバックス リミテッド
Publication of JP2013525420A publication Critical patent/JP2013525420A/ja
Publication of JP2013525420A5 publication Critical patent/JP2013525420A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2013506803A 2010-04-29 2011-04-29 抗ｃｄ３免疫分子療法により肝炎を治療する方法および組成物 Pending JP2013525420A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32955410P 2010-04-29 2010-04-29
US61/329,554 2010-04-29
PCT/IB2011/051900 WO2011135544A2 (en) 2010-04-29 2011-04-29 Methods and compositions for treating hepatitis with anti-cd3 immune molecule therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016096494A Division JP2016172759A (ja) 2010-04-29 2016-05-12 抗ｃｄ３免疫分子療法により肝炎を治療する方法および組成物

Publications (2)

Publication Number Publication Date
JP2013525420A true JP2013525420A (ja) 2013-06-20
JP2013525420A5 JP2013525420A5 (https=) 2014-05-29

Family

ID=44629291

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013506803A Pending JP2013525420A (ja) 2010-04-29 2011-04-29 抗ｃｄ３免疫分子療法により肝炎を治療する方法および組成物
JP2016096494A Pending JP2016172759A (ja) 2010-04-29 2016-05-12 抗ｃｄ３免疫分子療法により肝炎を治療する方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016096494A Pending JP2016172759A (ja) 2010-04-29 2016-05-12 抗ｃｄ３免疫分子療法により肝炎を治療する方法および組成物

Country Status (9)

Country Link
US (1) US20130078238A1 (https=)
EP (1) EP2563815A2 (https=)
JP (2) JP2013525420A (https=)
KR (1) KR20130066626A (https=)
CN (1) CN103038256A (https=)
AU (1) AU2011246893A1 (https=)
BR (1) BR112012027531A2 (https=)
CA (1) CA2804976A1 (https=)
WO (1) WO2011135544A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2892924B1 (en) * 2012-06-14 2020-11-25 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037860A1 (en) * 1999-11-26 2001-05-31 Unisearch Limited Method of inducing immune tolerance
JP2007511529A (ja) * 2003-11-14 2007-05-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫調節法
WO2009090656A2 (en) * 2008-01-18 2009-07-23 Hadasit Medical Research Services & Development Ltd. Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4654210A (en) 1979-04-26 1987-03-31 Ortho Pharmaceutical Corporation Methods and compositions using complement fixing monoclonal antibody to human T cells
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
WO1991006319A1 (en) 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
US8940479B2 (en) * 2008-01-14 2015-01-27 Cornell University Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037860A1 (en) * 1999-11-26 2001-05-31 Unisearch Limited Method of inducing immune tolerance
JP2007511529A (ja) * 2003-11-14 2007-05-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫調節法
WO2009090656A2 (en) * 2008-01-18 2009-07-23 Hadasit Medical Research Services & Development Ltd. Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6015016466; Ｊｏｕｒｎａｌ　ｏｆ　Ｈｅｐａｔｏｌｏｇｙ Ｖｏｌ．５０，　Ｎｏ．１, 2009, ｐ．Ｓ１８，　４１ *
JPN6015016467; Ｈｅｐａｔｏｌｏｇｙ Ｖｏｌ．５０，　Ｎｏ．４，　Ｓｕｐｐｌ, 2009, ｐ．８６３Ａ，　１２０１ *
JPN6015016468; 別冊・医学のあゆみ　消化器疾患　Ｖｅｒ．３　-ｓｔａｔｅ　ｏｆ　ａｒｔｓ　ＩＩ．肝・胆・膵 , 20061010, ｐ．２０-２５ *
JPN6015016469; 臨床検査 Ｖｏｌ．４８，　Ｎｏ．４, 2004, ｐ．４８２-４８９ *
JPN6015016471; 臨床消化器内科 Ｖｏｌ．１８，　Ｎｏ．９, 2003, ｐ．１２８１-１２８６ *
JPN6015016473; 薬理と治療 Ｖｏｌ．３５，　ｓｕｐｐｌ．３, 2007, ｐ．Ｓ．２５３-Ｓ．２５６ *

Also Published As

Publication number Publication date
WO2011135544A3 (en) 2012-01-05
US20130078238A1 (en) 2013-03-28
CA2804976A1 (en) 2011-11-03
CN103038256A (zh) 2013-04-10
WO2011135544A2 (en) 2011-11-03
EP2563815A2 (en) 2013-03-06
KR20130066626A (ko) 2013-06-20
AU2011246893A1 (en) 2012-11-08
JP2016172759A (ja) 2016-09-29
BR112012027531A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
JP2016172759A (ja) 抗ｃｄ３免疫分子療法により肝炎を治療する方法および組成物
CN105392497B (zh) 以il-4r抑制剂治疗嗜酸性食管炎的方法
TWI699212B (zh) 藉由投與ｉｌ-４ｒ拮抗劑治療異位性皮膚炎的方法
TWI697334B (zh) 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
ES2393674T3 (es) Métodos para modular la inmunidad
CN114558129A (zh) 用于降低心血管风险的方法
KR20190108144A (ko) 질환 및 장애의 치료 및 방지를 위한 단쇄 지방산의 용도
US9981037B2 (en) Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
JP7811933B2 (ja) 活動性好酸球性食道炎を治療する方法
WO2022075476A1 (en) Method for treating ox40 related disease
US20230227555A1 (en) Cd-3 antibodies for the treatment of coronavirus
IL323497A (en) Methods for treating eosinophilic gastroenteritis by administering an IL-4R antagonist
US20240336688A1 (en) Dual-blockade of il-4 signaling and immune checkpoint proteins for treating cancer
US20150132289A1 (en) Methods and compositions for treating psc (primary sclerosing cholangitis) or pbc (primary biliary cirrhosis) with anti-cd3 immune molecule therapy
WO2026096637A1 (en) Glp-1 agonists and foralumab combination therapies
JP2024538064A (ja) ミクログリア活性化を抑制するための方法
CN115916820A (zh) 用il6拮抗剂治疗包括covid-19肺炎在内的肺炎的方法
HK1145460A (en) TREATMENT OF TNFα RELATED DISORDERS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160112